

THIS ANNOUNCEMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS DOCUMENT.



Lowell signs supplemental indenture to consensually implement Proposed 50% Amendments (as defined herein); sets Expiration Time (as defined herein) for February 20, 2026

€466,931,106 Floating Rate Senior Secured Notes due 2029

(Regulation S Notes: ISIN XS3075000862, Common Code 307500086)

Rule 144A Notes: ISIN XS3075019888, Common Code 307501988)

(the “Existing FRNs”)

and

€967,562,961 9.500% Senior Secured Notes due 2028

(Regulation S Notes: ISIN XS3075026156, Common Code 307502615)

Rule 144A Notes: ISIN XS3075031586, Common Code 307503158)

(the “Existing SSNs” and, together with the Existing FRNs, the “Existing Notes”)

of

Garfunkelux Holdco 3 S.A.

(a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, with registered office at 488, route de Longwy, L-1940 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg Trade and Companies Register (*Registre de Commerce et des Sociétés, Luxembourg*) under registration number B197.551)

London, February 11, 2026

Lowell announces that it has signed a supplemental indenture to consensually implement the Proposed 50% Amendments. The Consent Solicitation will expire at 5:00 p.m., London time, on February 20, 2026.

Garfunkelux Holdco 3 S.A. (the “**Issuer**”, and together with Garfunkelux Holdco 2 S.A. and its subsidiaries, “**Lowell**” or “**Group**”) is pleased to announce that it has (i) received consents from Holders representing a majority in aggregate principal amount of the outstanding Existing Notes, which constitutes Requisite 50% Consents, and (ii) signed a supplemental indenture dated as of February 10, 2026 (the “**Supplemental Indenture**”) allowing for a consensual amendment of its existing indenture to extend the grace period for interest payments on the Existing Notes from 30 days to 120 days for each of (a) the interest payment due under the Existing FRNs on February 1, 2026 in respect of the interest period from November 1, 2025 to (but excluding) February 1, 2026; (b) the interest payment due under the Existing FRNs on May 1, 2026 in respect of the interest period from February 1, 2026 to (but excluding) May 1, 2026; and (c) the interest payment due under the Existing SSNs on May 1, 2026 in respect of the interest period from November 1, 2025 to (but excluding) May 1, 2026 (collectively, the “**Proposed 50% Amendments**”).

Expiration Time

Even though, the implementation of the Proposed 50% Amendments was not conditional on obtaining the Requisite 90% Consents, the Issuer decided to extend the expiration time of the Consent Solicitation to obtain the Requisite 90% Consents required for the Proposed 90% Amendments.

The Consent Solicitation, which was previously scheduled to expire at 5:00 p.m., London time, on February 12, 2026, has been extended to expire at 5:00 p.m., London time, on February 20, 2026, as the same may be further extended or earlier terminated by the Issuer in its sole discretion (such date and time, as the same may be extended, the “**Expiration Time**”).

All Existing Notes that were blocked in connection with the Consent Solicitation will be unblocked as soon as practicable after the Expiration Time.

Additional Information

The full details, including terms and conditions, of the Consent Solicitation are provided in the Issuer’s consent solicitation statement dated as of January 30, 2026 (the “**Consent Solicitation Statement**”). Capitalized terms used but not defined in this announcement have the meanings given to them in the Consent Solicitation Statement.

The Consent Solicitation Statement has been made available to all Holders through the Information and Tabulation Agent. If you have any questions about the Consent Solicitation, you should contact:

GLAS Specialist Services Limited

Address: 55 Ludgate Hill, Level 1, West, London EC4M 7JW, United Kingdom

Telephone: + 44 203 597 2940

Email: lm@glas.agency

Important notice

This announcement does not constitute an offer to sell or the solicitation of an offer to exchange, buy or subscribe the Existing Notes or any other security to or from any person in the United States or any jurisdiction and shall, in any circumstance, not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful. The Existing Notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or with any securities regulatory authority of any state or other jurisdiction of the United States or in any other jurisdiction.

This announcement may include “forward-looking statements” such as certain statements, estimates, targets and projections provided by the Issuer with respect to the anticipated future performance of the Issuer and the Group. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “could,” “estimates,” “anticipates,” “aims,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek,” “should” or “would” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. You should not place undue reliance on these forward-looking statements. Such forward-looking statements reflect significant assumptions and subjective judgments by the Issuer’s management concerning anticipated results. These assumptions and judgments may or may not prove to be correct and there can be no assurance that any estimates, targets or projections are attainable or will be realized. Accordingly, neither the Issuer nor any member of the Group (nor any of its or their respective directors, partners, employees or advisers) nor any other person, shall give any representation or warranty as to the achievements or reasonableness of future projections, estimates or targets nor will they be liable for any direct, indirect or consequential loss or

damage suffered by any person as a result of relying on any statement in or omission from this announcement; any such liability is expressly disclaimed. Any forward-looking statements are only made as of the date of this announcement, and we do not intend, and do not assume any obligation, to update forward-looking statements set forth in this announcement. You should interpret all subsequent written or oral forward-looking statements attributable to the Issuer or to persons acting on its behalf as being qualified by the cautionary statements in this note. As a result, you should not place undue reliance on these forward-looking statements.